+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Neutropenia Treatment Market - Global Forecast 2026-2032- Product Image
Neutropenia Treatment Market - Global Forecast 2026-2032- Product Image
New

Neutropenia Treatment Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 198 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 5674204
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The neutropenia treatment market is evolving rapidly as payers, clinicians, and manufacturers respond to new therapeutic advances, operational challenges, and changing regulatory environments. This report provides senior decision-makers with a structured, evidence-based overview of market forces and actionable insights to inform strategic planning and investment in neutropenia therapies.

Market Snapshot

The Neutropenia Treatment Market grew from USD 15.85 billion in 2025 to USD 16.65 billion in 2026. It is expected to continue growing at a CAGR of 5.16%, reaching USD 22.54 billion by 2032. Demand is being shaped by evolving clinical priorities, a focus on cost-effectiveness, and significant advancements in both biologic and biosimilar therapies. Stakeholders are increasingly adopting innovative models, such as value-based contracts and real-world evidence collection, to secure adoption in diverse care settings.

Scope & Segmentation

  • Treatment Types: Analysis covers filgrastim, lenograstim, and pegfilgrastim therapies, capturing short- and long-acting options for both inpatient management and outpatient prophylaxis.
  • Dosing Variants: Segmentation spans 300 mcg, 480 mcg, and 600 mcg for filgrastim; 3 mg and 5 mg for lenograstim; and 6 mg for pegfilgrastim.
  • Therapy Classes: Detailed assessment of biosimilar and originator products, highlighting distinctions that drive pricing strategies and procurement.
  • Administration Routes: Comparative analysis of intravenous and subcutaneous delivery, evaluating implications for site-of-care and patient support.
  • Distribution Channels: Includes hospital pharmacy (inpatient and outpatient), online pharmacy, retail pharmacy (chain and independent).
  • End Users: Profiles ambulatory care centers, clinics, home care providers, and public and private hospitals.
  • Patient Age Cohorts: Separate consideration for adult, pediatric, and geriatric populations with an emphasis on safety, dosing, and adherence requirements.
  • Severity Categories: Market analysis incorporates mild, moderate, and severe neutropenia, recognizing differences in monitoring and escalation needs.
  • Regions Covered: Insight into the Americas, Europe, Middle East & Africa, and Asia-Pacific, with emphasis on regulatory environments and market access strategies.

Key Takeaways

  • The neutropenia treatment landscape has become increasingly complex, with decision-making shaped by therapeutic innovation, regulatory evolution, and reimbursement pressures.
  • Growth in biosimilars introduces new options for prescribers and procurement teams, reinforcing the need for robust value demonstrations and adaptable commercial models.
  • Hospitals and ambulatory providers are updating protocols by weighing clinical efficacy, safety profiles, administration preferences, and the realities of outpatient expansion.
  • Regional market differences drive tailored product launches, procurement cycles, and care pathways, making local stakeholder engagement and regulatory mastery critical for success.
  • Collaboration across manufacturers, distributors, and care providers is increasing, with emphasis on supply chain reliability, clinician education, and streamlined transitions of care.

Tariff Impact

Adjustments to tariff policies enacted in 2025 produced notable consequences for the neutropenia treatment supply chain, especially regarding sources of active pharmaceutical ingredients and single-use devices. Industry players responded by intensifying supplier risk assessment, diversifying procurement channels, and strengthening localized manufacturing. These measures affected commercial negotiations and placed additional scrutiny on supply reliability in contracting, ultimately supporting more resilient and cost-effective delivery frameworks.

Methodology & Data Sources

This report employs a layered methodology, integrating structured interviews with clinical, pharmacy, and supply chain leaders, along with a thorough literature synthesis including regulatory documents, payer statements, and clinical data. Triangulation across sources clarifies product, segment, and operational differences, while segment and regional analyses enhance the relevance for strategic and tactical decision-making.

Why This Report Matters

  • Supports executive-level forecasting and strategic investment by providing a comprehensive and segmented view of market dynamics.
  • Equips senior leaders with actionable insights into regulatory trends, procurement priorities, and care delivery models shaping neutropenia therapy adoption.
  • Enables informed supply chain, commercialization, and partnership decisions in a highly regulated and evolving therapeutic environment.

Conclusion

Sustained success in neutropenia treatment requires alignment of clinical evidence, innovative delivery models, and supply chain resilience. Strategic integration of these priorities will optimize outcomes for providers, payers, and patients in the evolving market.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Neutropenia Treatment Market, by Treatment Type
8.1. Filgrastim
8.1.1. 300 mcg
8.1.2. 480 mcg
8.1.3. 600 mcg
8.2. Lenograstim
8.2.1. 3 mg
8.2.2. 5 mg
9. Neutropenia Treatment Market, by Therapy Class
9.1. Biosimilar
9.2. Originator
10. Neutropenia Treatment Market, by Route Of Administration
10.1. Intravenous Injection
10.2. Subcutaneous Injection
11. Neutropenia Treatment Market, by Patient Age Group
11.1. Adult
11.2. Geriatric
11.3. Pediatric
12. Neutropenia Treatment Market, by Severity
12.1. Mild
12.2. Moderate
12.3. Severe
13. Neutropenia Treatment Market, by Distribution Channel
13.1. Hospital Pharmacy
13.1.1. Inpatient Pharmacy
13.1.2. Outpatient Pharmacy
13.2. Online Pharmacy
13.3. Retail Pharmacy
13.3.1. Chain Pharmacy
13.3.2. Independent Pharmacy
14. Neutropenia Treatment Market, by End User
14.1. Ambulatory Care Centers
14.2. Clinics
14.3. Home Care
14.4. Hospitals
14.4.1. Private
14.4.2. Public
15. Neutropenia Treatment Market, by Region
15.1. Americas
15.1.1. North America
15.1.2. Latin America
15.2. Europe, Middle East & Africa
15.2.1. Europe
15.2.2. Middle East
15.2.3. Africa
15.3. Asia-Pacific
16. Neutropenia Treatment Market, by Group
16.1. ASEAN
16.2. GCC
16.3. European Union
16.4. BRICS
16.5. G7
16.6. NATO
17. Neutropenia Treatment Market, by Country
17.1. United States
17.2. Canada
17.3. Mexico
17.4. Brazil
17.5. United Kingdom
17.6. Germany
17.7. France
17.8. Russia
17.9. Italy
17.10. Spain
17.11. China
17.12. India
17.13. Japan
17.14. Australia
17.15. South Korea
18. United States Neutropenia Treatment Market
19. China Neutropenia Treatment Market
20. Competitive Landscape
20.1. Market Concentration Analysis, 2025
20.1.1. Concentration Ratio (CR)
20.1.2. Herfindahl Hirschman Index (HHI)
20.2. Recent Developments & Impact Analysis, 2025
20.3. Product Portfolio Analysis, 2025
20.4. Benchmarking Analysis, 2025
20.5. AbbVie Inc.
20.6. Amgen Inc.
20.7. Baxter International Inc.
20.8. Biocon Limited
20.9. Celltrion, Inc.
20.10. Coherus BioSciences, Inc.
20.11. Fresenius Kabi AG
20.12. Intas Pharmaceuticals Ltd.
20.13. Pfizer Inc.
20.14. Sandoz International GmbH
20.15. Teva Pharmaceutical Industries Ltd.
20.16. Viatris Inc.
List of Figures
FIGURE 1. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL NEUTROPENIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL NEUTROPENIA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 13. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. UNITED STATES NEUTROPENIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 15. CHINA NEUTROPENIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY 300 MCG, BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY 300 MCG, BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY 300 MCG, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY 480 MCG, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY 480 MCG, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY 480 MCG, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY 600 MCG, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY 600 MCG, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY 600 MCG, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY 3 MG, BY REGION, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY 3 MG, BY GROUP, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY 3 MG, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY 5 MG, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY 5 MG, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY 5 MG, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY BIOSIMILAR, BY REGION, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY BIOSIMILAR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY BIOSIMILAR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY ORIGINATOR, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY ORIGINATOR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY ORIGINATOR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY INTRAVENOUS INJECTION, BY REGION, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY INTRAVENOUS INJECTION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY INTRAVENOUS INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY REGION, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY MILD, BY REGION, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY MILD, BY GROUP, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY MILD, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY MODERATE, BY REGION, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY MODERATE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY MODERATE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERE, BY REGION, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY INPATIENT PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY INPATIENT PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY INPATIENT PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY OUTPATIENT PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY OUTPATIENT PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY OUTPATIENT PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY CHAIN PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY CHAIN PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY INDEPENDENT PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY INDEPENDENT PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY PRIVATE, BY REGION, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY PRIVATE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 100. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY PRIVATE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 101. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY PUBLIC, BY REGION, 2018-2032 (USD MILLION)
TABLE 102. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY PUBLIC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 103. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY PUBLIC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 104. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 105. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 106. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 107. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2018-2032 (USD MILLION)
TABLE 108. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2018-2032 (USD MILLION)
TABLE 109. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
TABLE 110. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 111. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 112. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2018-2032 (USD MILLION)
TABLE 113. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 114. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
TABLE 115. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
TABLE 116. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 117. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 118. NORTH AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 119. NORTH AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 120. NORTH AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2018-2032 (USD MILLION)
TABLE 121. NORTH AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2018-2032 (USD MILLION)
TABLE 122. NORTH AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
TABLE 123. NORTH AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 124. NORTH AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 125. NORTH AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2018-2032 (USD MILLION)
TABLE 126. NORTH AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 127. NORTH AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
TABLE 128. NORTH AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
TABLE 129. NORTH AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 130. NORTH AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 131. LATIN AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 132. LATIN AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 133. LATIN AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2018-2032 (USD MILLION)
TABLE 134. LATIN AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2018-2032 (USD MILLION)
TABLE 135. LATIN AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
TABLE 136. LATIN AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 137. LATIN AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 138. LATIN AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2018-2032 (USD MILLION)
TABLE 139. LATIN AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 140. LATIN AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
TABLE 141. LATIN AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
TABLE 142. LATIN AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 143. LATIN AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 144. EUROPE, MIDDLE EAST & AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 145. EUROPE, MIDDLE EAST & AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 146. EUROPE, MIDDLE EAST & AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2018-2032 (USD MILLION)
TABLE 147. EUROPE, MIDDLE EAST & AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2018-2032 (USD MILLION)
TABLE 148. EUROPE, MIDDLE EAST & AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
TABLE 149. EUROPE, MIDDLE EAST & AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 150. EUROPE, MIDDLE EAST & AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 151. EUROPE, MIDDLE EAST & AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2018-2032 (USD MILLION)
TABLE 152. EUROPE, MIDDLE EAST & AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 153. EUROPE, MIDDLE EAST & AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
TABLE 154. EUROPE, MIDDLE EAST & AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
TABLE 155. EUROPE, MIDDLE EAST & AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 156. EUROPE, MIDDLE EAST & AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 157. EUROPE NEUTROPENIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 158. EUROPE NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 159. EUROPE NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2018-2032 (USD MILLION)
TABLE 160. EUROPE NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2018-2032 (USD MILLION)
TABLE 161. EUROPE NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
TABLE 162. EUROPE NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 163. EUROPE NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 164. EUROPE NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2018-2032 (USD MILLION)
TABLE 165. EUROPE NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 166. EUROPE NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
TABLE 167. EUROPE NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
TABLE 168. EUROPE NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 169. EUROPE NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 170. MIDDLE EAST NEUTROPENIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 171. MIDDLE EAST NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 172. MIDDLE EAST NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2018-2032 (USD MILLION)
TABLE 173. MIDDLE EAST NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2018-2032 (USD MILLION)
TABLE 174. MIDDLE EAST NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
TABLE 175. MIDDLE EAST NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 176. MIDDLE EAST NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 177. MIDDLE EAST NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2018-2032 (USD MILLION)
TABLE 178. MIDDLE EAST NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 179. MIDDLE EAST NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
TABLE 180. MIDDLE EAST NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
TABLE 181. MIDDLE EAST NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 182. MIDDLE EAST NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 183. AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 184. AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 185. AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2018-2032 (USD MILLION)
TABLE 186. AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2018-2032 (USD MILLION)
TABLE 187. AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
TABLE 188. AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 189. AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 190. AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2018-2032 (USD MILLION)
TABLE 191. AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 192. AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
TABLE 193. AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
TABLE 194. AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 195. AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 196. ASIA-PACIFIC NEUTROPENIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 197. ASIA-PACIFIC NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 198. ASIA-PACIFIC NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2018-2032 (USD MILLION)
TABLE 199. ASIA-PACIFIC NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2018-2032 (USD MILLION)
TABLE 200. ASIA-PACIFIC NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
TABLE 201. ASIA-PACIFIC NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 202. ASIA-PACIFIC NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 203. ASIA-PACIFIC NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2018-2032 (USD MILLION)
TABLE 204. ASIA-PACIFIC NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 205. ASIA-PACIFIC NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
TABLE 206. ASIA-PACIFIC NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
TABLE 207. ASIA-PACIFIC NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 208. ASIA-PACIFIC NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 209. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 210. ASEAN NEUTROPENIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 211. ASEAN NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 212. ASEAN NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2018-2032 (USD MILLION)
TABLE 213. ASEAN NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2018-2032 (USD MILLION)
TABLE 214. ASEAN NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
TABLE 215. ASEAN NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 216. ASEAN NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 217. ASEAN NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2018-2032 (USD MILLION)
TABLE 218. ASEAN NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 219. ASEAN NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
TABLE 220. ASEAN NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
TABLE 221. ASEAN NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 222. ASEAN NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 223. GCC NEUTROPENIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 224. GCC NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 225. GCC NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2018-2032 (USD MILLION)
TABLE 226. GCC NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2018-2032 (USD MILLION)
TABLE 227. GCC NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
TABLE 228. GCC NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 229. GCC NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 230. GCC NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2018-2032 (USD MILLION)
TABLE 231. GCC NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 232. GCC NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
TABLE 233. GCC NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
TABLE 234. GCC NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 235. GCC NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 236. EUROPEAN UNION NEUTROPENIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 237. EUROPEAN UNION NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 238. EUROPEAN UNION NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2018-2032 (USD MILLION)
TABLE 239. EUROPEAN UNION NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2018-2032 (USD MILLION)
TABLE 240. EUROPEAN UNION NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
TABLE 241. EUROPEAN UNION NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 242. EUROPEAN UNION NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 243. EUROPEAN UNION NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2018-2032 (USD MILLION)
TABLE 244. EUROPEAN UNION NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 245. EUROPEAN UNION NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
TABLE 246. EUROPEAN UNION NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
TABLE 247. EUROPEAN UNION NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 248. EUROPEAN UNION NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 249. BRICS NEUTROPENIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 250. BRICS NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 251. BRICS NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2018-2032 (USD MILLION)
TABLE 252. BRICS NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2018-2032 (USD MILLION)
TABLE 253. BRICS NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
TABLE 254. BRICS NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 255. BRICS NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 256. BRICS NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2018-2032 (USD MILLION)
TABLE 257. BRICS NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 258. BRICS NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
TABLE 259. BRICS NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
TABLE 260. BRICS NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 261. BRICS NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 262. G7 NEUTROPENIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 263. G7 NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 264. G7 NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2018-2032 (USD MILLION)
TABLE 265. G7 NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2018-2032 (USD MILLION)
TABLE 266. G7 NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
TABLE 267. G7 NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 268. G7 NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 269. G7 NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2018-2032 (USD MILLION)
TABLE 270. G7 NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 271. G7 NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
TABLE 272. G7 NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
TABLE 273. G7 NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 274. G7 NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 275. NATO NEUTROPENIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 276. NATO NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 277. NATO NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2018-2032 (USD MILLION)
TABLE 278. NATO NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2018-2032 (USD MILLION)
TABLE 279. NATO NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
TABLE 280. NATO NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 281. NATO NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 282. NATO NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2018-2032 (USD MILLION)
TABLE 283. NATO NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 284. NATO NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
TABLE 285. NATO NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
TABLE 286. NATO NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 287. NATO NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 288. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 289. UNITED STATES NEUTROPENIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 290. UNITED STATES NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 291. UNITED STATES NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2018-2032 (USD MILLION)
TABLE 292. UNITED STATES NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2018-2032 (USD MILLION)
TABLE 293. UNITED STATES NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
TABLE 294. UNITED STATES NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 295. UNITED STATES NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 296. UNITED STATES NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2018-2032 (USD MILLION)
TABLE 297. UNITED STATES NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 298. UNITED STATES NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
TABLE 299. UNITED STATES NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
TABLE 300. UNITED STATES NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 301. UNITED STATES NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 302. CHINA NEUTROPENIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 303. CHINA NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 304. CHINA NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2018-2032 (USD MILLION)
TABLE 305. CHINA NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2018-2032 (USD MILLION)
TABLE 306. CHINA NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
TABLE 307. CHINA NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 308. CHINA NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 309. CHINA NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2018-2032 (USD MILLION)
TABLE 310. CHINA NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 311. CHINA NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
TABLE 312. CHINA NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
TABLE 313. CHINA NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 314. CHINA NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Neutropenia Treatment market report include:
  • AbbVie Inc.
  • Amgen Inc.
  • Baxter International Inc.
  • Biocon Limited
  • Celltrion, Inc.
  • Coherus BioSciences, Inc.
  • Fresenius Kabi AG
  • Intas Pharmaceuticals Ltd.
  • Pfizer Inc.
  • Sandoz International GmbH
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.

Table Information

Report AttributeDetails
No. of Pages198
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 16.65 Billion
Forecasted Market Value ( USD ) by 2032 $ 22.54 Billion
Compound Annual Growth Rate5.1%
Regions CoveredGlobal
No. of Companies Mentioned13

Related Topics

Related Reports

Chemotherapy Induced Neutropenia Market - Global Forecast 2026-2032 - Product Image

Chemotherapy Induced Neutropenia Market - Global Forecast 2026-2032

  • Report
  • 196 Pages
  • Global
From
Febrile Neutropenia Market - Product Image

Febrile Neutropenia Market

  • Report
  • 250 Pages
  • Global
From
Chemotherapy-Induced Neutropenia Treatment - Global Strategic Business Report - Product Image

Chemotherapy-Induced Neutropenia Treatment - Global Strategic Business Report

  • Report
  • 381 Pages
  • Global
From
Chemotherapy-induced Neutropenia Treatment Market Size, Share & Trends Analysis Report By Treatment (Growth Factors, Antibiotics), By Drug, By Route of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Chemotherapy-induced Neutropenia Treatment Market Size, Share & Trends Analysis Report By Treatment (Growth Factors, Antibiotics), By Drug, By Route of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 195 Pages
  • Global
From
Febrile Neutropenia Drug Pipeline Analysis Report 2025 - Product Image

Febrile Neutropenia Drug Pipeline Analysis Report 2025

  • Drug Pipelines
  • 200 Pages
  • Global
From

About the Neutropenia Drug Market

Neutropenia Drug is a type of drug used to treat immune disorders, specifically those that involve a decrease in the number of neutrophils, a type of white blood cell. Neutropenia can be caused by a variety of conditions, including chemotherapy, radiation therapy, and certain infections. Neutropenia drugs are designed to increase the number of neutrophils in the body, helping to reduce the risk of infection and other complications. These drugs are typically administered intravenously or orally, depending on the severity of the condition. The Neutropenia Drug market is highly competitive, with a number of companies offering products to treat this condition. Some of the major players in this market include Amgen, Novartis, Pfizer, Merck, and Roche. These companies offer a range of products, including monoclonal antibodies, cytokines, and other biologics. Additionally, there are a number of smaller companies that offer generic versions of these drugs. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.